February 27, 2023 10:43 AM ESTUpdated 11:16 AM
People

Tiny Apex­i­gen to lay off ma­jor­i­ty of work­ers af­ter SPAC deal

Paul Schloesser

Associate Editor

An­oth­er biotech is fac­ing in­dus­try head­winds and cut­ting more than half of its em­ploy­ees.

Cal­i­for­nia biotech Apex­i­gen an­nounced Mon­day morn­ing that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times